Floatz logo

PREFEST COMPONENT NORGESTIMATE

Depressive Disorder, Major

Eli Lilly and CompanySmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Depressive Disorder, Major cohort.

Asset / SponsorPhaseRating
Amitriptyline
Janssen Research & Development, LLC
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
Pregabalin
Janssen Research & Development, LLC
Phase 4BBB
Seroquel®
Janssen Research & Development, LLC
Phase 4BBB
Paroxetine
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 4BB

View all 50 →

Same molecule, other indications

PREFEST COMPONENT NORGESTIMATE is also rated in:

Ovary CystDormant
B
Indicative ·
57 / 100
View asset →
migraine disorderDormant
CC
Indicative ·
47 / 100
View asset →
cystic fibrosisDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →